This June, the CDRP will host the Mt. Hood Diabetes Challenge, an international conference for researchers and policy analysts working in health economics and disease simulation modeling in the field of diabetes.
“I was seeing the rise in cases not only at the University of Chicago but across the city and nationally. I thought, ‘This is a disease that’s preventable and treatable—one shot of penicillin, or at most three—and it’s cured. Why is this still happening?’”
Join a national conversation on health equity on May 5 and May 9
Are GLP-1 drug benefits worth their enormous cost? The answer right now is no, according to a new study published in JAMA Health Forum by CDRP researchers Jennifer Hwang, Neda Laiteerapong, Elbert Huang, and David D. Kim